NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. NanoViricides is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform.

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

NanoViricides Inc (NYSE-A:NNVC) has announced that clinical trials for its broad-spectrum antiviral drug NV-CoV-2 commenced on June 17, 2023. The trials will evaluate the safety and efficacy of two oral drug products: NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.

NanoViricides commences clinical trials for its broad-spectrum antiviral drug NV-CoV-2

SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. "We believe that the start of the Phase 1a/1b safety and efficacy clinical trial is an important milestone not only for NanoViricides and Karveer Meditech, India, but for the whole world," said Dr. Anil Diwan, Ph.D.

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Apollomics Inc

Kaixin Auto Holdings

Reunion Neuroscience Inc

MultiMetaVerse Holdings Ltd

SciSparc Ltd

Wearable Devices Ltd

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.

The 7 Most Promising Penny Stocks to Buy in June

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET. Event BIO International Convention Dates June 5-8, 2023 Location Boston Convention & Exhibition Center (BCEC), Boston, MA, USA.

NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

NanoViricides (NYSE-A:NNVC) Inc has reported its financial results for the fiscal third quarter that revealed ample cash on hand, giving the company scope to kick off its clinical trials of its broad-spectrum antivirals, including lead COVID drug candidate NV-CoV-2. Investors reacted to the news sending NanoViricides (NYSE-A:NNVC) shares up nearly 1.8% in morning trade.

NanoViricides ends fiscal 3Q with strong cash runway to begin clinical trials of broad-spectrum COVID drug

SHELTON, CT / ACCESSWIRE / May 16, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission (SEC) on Monday, May 15, 2023. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000141057823001235/nnvc-20230331x10q.htm).

NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American:  NNVC ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that Anil R. Diwan, Ph.D., President of the Company will be presenting at The Inaugural EF Hutton Global Conference, which will be held on May 10-11, 2023, at the Plaza Hotel in the heart of New York City. NanoViricides is presenting on May 10th.

NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City

SHELTON, CT / ACCESSWIRE / April 25, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate. NV-387 has been found to have broad-spectrum activity against all of the tested seasonal coronaviruses and SARS-CoV-2 in pre-clinical studies.

NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient

SHELTON, CT / ACCESSWIRE / April 17, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer").

NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate

SHELTON, CT / ACCESSWIRE / April 4, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer").

NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates

SHELTON, CT / ACCESSWIRE / February 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission (SEC) on Tuesday, February 14, 2023. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057823000129/nnvc-20221231x10q.htm).

NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials

SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase™ 2023 Conference in San Fransisco on Monday, January 9th at 10:30pm PT.

NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

SHELTON, CT / ACCESSWIRE / December 5, 2022 / NanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET.

NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET

SHELTON, CT / ACCESSWIRE / November 15, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022 with the Securities and Exchange Commission (SEC) on Monday, November 14, 2022. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057822003398/nnvc-20220930x10q.htm ).

NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage

Jupiter Wellness

Mind Medicine MindMed

Oblong

Seelos Therapeutics

Smart Sand

Capstone Green Energy

Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

SHELTON, CT / ACCESSWIRE / October 14, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission (SEC) on Thursday, October 13, 2022. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057822002878/nnvc-20220630x10k.htm).

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

SHELTON, CT / ACCESSWIRE / August 9, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus. The Company believes its Monkeypox drug development program should reach the clinic in a much shorter timespan compared to its NV-CoV-2 drug for treating COVID-19 SARS-CoV-2 virus infection.

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

Aethlon Medical

Applied DNA Sciences

Chembio Diagnostics

E-Home Household Service Holdings Ltd

SIGA Technologies

Tonix Pharmaceuticals Hld

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Shares of NanoViricides Inc. NNVC, +19.42% jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized therapies for monkeypox, though the Food and Drug Administration said last month that it's allowing prescriptions of the antiviral Tpoxx through a compassionate-use pathway.

NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment

SHELTON, CT / ACCESSWIRE / August 4, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus. Specifically, the Company has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against certain poxviruses in order to develop broad-spectrum poxvirus therapeutics that act by mechanisms other than tecovirimat (TPOXX®).

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission. This press release should be read in conjunction with the Company's Form 10-Q filed yesterday, May 16, 2022.

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says.

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis. Specifically, the Company has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children, causing liver transplants as well as fatalities in large percentages of cases.

NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform is providing an update on its clinical-trial ready Coronavirus Oral and Injectable Drug Programs. NanoViricides is close to completing an Investigators Medicinal Product Dossier that is required as part of the clinical trial application for its lead drug candidate for the treatment of COVID-19, NV-CoV-2.

News for NanoViricides Stock (NNVC)